Fagron NV/€FAGR

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About Fagron NV

Fagron NV is a pharmaceutical company specializing in pharmaceutical compounding, providing personalized medical solutions to hospitals, pharmacies, clinics, and patients across more than 30 countries. The company operates through three segments: Essentials, offering pharmaceutical raw materials and equipment; Brands, developing innovative compounding concepts and formulations; and Compounding Services, delivering ready-to-use medications from its sterile and non-sterile facilities. Founded in 1990 in Rotterdam, the Netherlands, Fagron has expanded its operations globally, with its registered office in Nazareth, Belgium, and operational headquarters in Rotterdam. The company's strategic focus on innovation and quality has enabled it to establish a significant presence in the pharmaceutical compounding market.

Ticker

€FAGR

Primary listing

BSE

Industry

Health Care Providers & Services
Headquarters

Employees

3,828

ISIN

BE0003874915

Fagron NV Metrics

BasicAdvanced
€1.6B
20.21
€1.10
0.27
€0.25
1.10%

Bulls say / Bears say

Fagron reported a 13% organic revenue growth at constant exchange rates in Q4 2024, with total revenue reaching €172 million, indicating strong market demand and operational efficiency. (gurufocus.com)
The company announced six acquisitions between the end of 2024 and early 2025, strengthening its market position and demonstrating financial discipline. (gurufocus.com)
Fagron's proposed dividend of €0.35 per share represents a 17% increase compared to 2023, reflecting strong financial performance and commitment to shareholder returns. (gurufocus.com)
The FDA issued a warning letter to Fagron regarding its Wichita facility, with corrective actions still being implemented, which could impact operations and reputation. (gurufocus.com)
Operating costs increased by 18.6% year on year, mainly due to growth in Compounding Services in North America and the impact of acquisitions, potentially affecting profit margins. (gurufocus.com)
The competitive environment in Latin America remains challenging, which could impact Fagron's growth and profitability in the region. (finance.yahoo.com)
Data summarised monthly by Lightyear AI. Last updated on 3 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €FAGR

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs